Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Allergy · 2024-06 · 79 (6) · 1501-1515
DOI: 10.1111/all.16009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 08.01.2024. Verfasst von Svenja Müller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 155-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This article was funded by the Christine Kühne-Center for Allergy Research and Education (CK-CARE).
Abstract (Originalsprache)
Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 in 2021), lebrikizumab (anti‐IL‐13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020 in the EU) or JAK1 (upadacitinib in 2021 and abrocitinib in 2022). Herein, we give an update on new approvals, long‐term safety, and efficacy. Upadacitinib and abrocitinib have the highest short‐term efficacy among the approved systemic therapies. In responders, dupilumab and tralokinumab catch up regarding long‐term efficacy and incremental clinical benefit within continuous use. Recently, the European Medicines Agency has released recommendations for the use of JAKi in patients at risk (cardiovascular and thromboembolic diseases, malignancies, (former) smoking, and age ≥65 years). Furthermore, we give an overview on emerging therapies currently in Phase III trials. Among the topical therapies, tapinarof (aryl hydrocarbon receptor), ruxolitinib (JAK1/2i), delgocitinib (pan‐JAKi), asivatrep (anti‐transient receptor potential vanilloid), and phosphodiesterase‐4‐inhibitors (roflumilast, difamilast) are discussed. Among systemic therapies, current data on cord‐blood‐derived mesenchymal stem cells, CM310 (anti IL‐4Rα), nemolizumab (anti‐IL‐31RA), anti‐OX40/OX40L‐antibodies, neurokinin‐receptor‐1‐antagonists, and difelikefalin (κ‐opioid‐R) are reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
- Christine Kühne Center for Allergy Research and Education Davos (CK-CARE), Davos, Switzerland.
- Davos BioSciences, Davos, Switzerland.
ORCID-Profile: Svenja Müller, Laura Maintz, Thomas Bieber
Förderung
- This article was funded by the Christine Kühne-Center for Allergy Research and Education (CK-CARE)
Zitieren
APA
Müller, S., Maintz, L., & Bieber, T. (2024). Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy, 79(6), 1501-1515. https://doi.org/10.1111/all.16009
Vancouver
Müller S, Maintz L, Bieber T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy. 2024;79(6):1501-1515. doi:10.1111/all.16009
BibTeX
@article{Mller2024,
author = {Müller, Svenja and Maintz, Laura and Bieber, Thomas},
title = {Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs},
journal = {Allergy},
year = {2024},
volume = {79},
number = {6},
pages = {1501--1515},
doi = {10.1111/all.16009}
}
EUVIMED